1stOncology™: Cancer Intelligence Service – Page 9769 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

CytomX Therapeutics to Host Virtual Investor Event on April 7, 2021

On March 24, 2021 CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage, oncology-focused biopharmaceutical company pioneering a novel class of investigational conditionally activated antibody therapeutics based on its Probody technology platform, reported that it will host a virtual investor event at 1:00 p.m. – 3:00 p.m. ET / 10:00 a.m. – 12:00 p.m. PT on Wednesday, April 7, 2021 (Press release, CytomX Therapeutics, MAR 24, 2021, View Source [SID1234577088]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

In addition to company executives, CytomX’s investor event will feature presentations from and an interactive Q&A session with industry experts, including:

John Lambert Ph.D., Queen’s University Belfast, an expert on conditionally activated antibody-drug conjugates (ADCs),
Sara M. Tolaney, M.D., Dana-Farber Cancer Institute, Harvard Medical School, an expert in breast oncology, and
Melissa L. Johnson, M.D., Sarah Cannon Research Institute, an expert in lung cancer.
The event will focus on CytomX’s Probody technology platform and the two conditionally activated ADCs, praluzatamab ravtansine (CX-2009) and CX-2029.

A live webcast will be available on the Events and Presentations section of CytomX’s website, www.cytomx.com. A replay of the webcast will be available for 30 days following the presentation.

Theratechnologies Announces First Patient Dosed In Phase 1 Clinical Trial Of TH1902 For Sortilin Positive Solid Tumors

On March 24, 2021 Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported that the first patient received a dose of TH1902, its lead peptide-drug conjugate (PDC) for the treatment of sortilin positive (SORT1+) solid tumors (Press release, Theratechnologies, MAR 24, 2021, View Source [SID1234577087]).

"This is yet another major achievement for our oncology program. Given the important medical need for novel, targeted cancer treatments, the rapid progression of our promising, unique and innovative approach to fight cancer is a great source of hope for patients," said Paul Lévesque, President and CEO, Theratechnologies.

"Despite the progress made in recent years in the field of oncology, many patients are unfortunately not responding to current treatments or do not tolerate them well. Targeting the sortilin receptor is an exciting and promising new approach for the potential treatment of cancer. Dosing the first patient with TH1902 brings us closer to a potential much needed new option in oncology," said Dr. Satish Shah, Medical Director, Gettysburg Cancer Center, Gettysburg, Pennsylvania and Dr. Tina Khair, Research Director, Gettysburg Cancer Center.

For the complete version, please download the PDF document.

4QYE 2020 Financial Results Conference Call and Webcast

On March 24, 2021 Crinetics reported that it will host a webcast and conference call to discuss its 2021 clinical plans and financial results for the fourth quarter and full year 2020 (Press release, Crinetics Pharmaceuticals, MAR 24, 2021, View Source [SID1234577086]). Following the live event, the archived webcast will be available for 90 days.

Webcast: 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results

On March 24, 2021 Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, reported that it will host a webcast and conference call on Tuesday, March 30, 2021 at 4:30 p.m. ET to discuss its 2021 clinical plans and financial results for the fourth quarter and full year 2020 (Press release, Crinetics Pharmaceuticals, MAR 24, 2021, View Source [SID1234577085]).

To access the webcast, please visit this link to the event. To participate by phone, please dial 877-407-0789 (domestic) or 201-689-8562 (international) and refer to conference ID 13717687. Following the live event, the archived webcast will be available for 90 days.

Enterome Receives FDA IND Clearance for EO2463, an ‘OncoMimic’ based Immunotherapy Targeting Liquid Tumors

On March 24, 2021 ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, reported that it has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with a Phase 1/2 clinical trial of EO2463, a potential treatment for indolent non-Hodgkin B-cell lymphomas (iNHL) (Press release, Enterome, MAR 24, 2021, View Source;utm_medium=rss&utm_campaign=enterome-receives-fda-ind-clearance-for-eo2463-an-oncomimic-based-immunotherapy-targeting-liquid-tumors [SID1234577084]). EO2463 will be Enterome’s second OncoMimics candidate to enter the clinic.

EO2463 is an innovative, off-the-shelf immuno-oncology candidate that combines four OncoMimics of B lymphocytes-specific lineage markers. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes enriched in iNHL.

OncoMimics are peptides, derived from bacteria present in the gut microbiome, that closely mimic either overexpressed tumor-associated antigen (TAA) or lineage-specific markers in solid and liquid tumors, respectively. OncoMimics are selected based on their ability to trigger the rapid activation of memory T-cells that were previously exposed to gut bacteria antigens similar to TAAs, and to direct a targeted cell-killing immune response against the tumor.

The primary objective of the study is to demonstrate safety, tolerability and efficacy of EO2463 as a monotherapy and in combination with standard of care (rituximab and rituximab in combination with lenalidomide) in 60 patients with follicular lymphoma (FL) and marginal zone lymphoma (MZL).

"With EO2463, we are expanding the potential utility of our OncoMimics pipeline into the field of liquid tumors. This milestone highlights the rapid progress that we are making with this potentially transformative cancer immunotherapy approach and builds on the ongoing trials of EO2401 in glioblastoma and in adrenal tumors. We are extremely excited by our OncoMimics approach as we believe it can be used to target any tumor antigen, and thus has therapeutic potential across all cancers. We look forward to updating you on the progress of this clinical trial, which is expected to start in the second quarter of 2021," said Jan Fagerberg, Chief Medical Officer of Enterome.